Vol 55, No 1 (2021)
Research Paper
Published online: 2020-12-14

open access

Page views 1481
Article views/downloads 724
Get Citation

Connect on Social Media

Connect on Social Media

Neutrophil-to-lymphocyte ratio (NLR) at boundaries of Progressive Supranuclear Palsy Syndrome (PSPS) and Corticobasal Syndrome (CBS)

Piotr Alster1, Natalia Madetko1, Andrzej Friedman1
Pubmed: 33315235
Neurol Neurochir Pol 2021;55(1):97-101.


Aim of the study. To examine possible features of neuroinflammation in progressive supranuclear palsy — Richardson syndrome and corticobasal syndrome (CBS).

Clinical rationale for the study. Neutrophil-to-lymphocyte ratio (NLR) is a parameter reflecting inflammation used in numerous branches of medicine. The search for pathogenesis of the diseases partly related to inflammatory processes confirms the need to obtain possible factors which could be relatively easily verified. NLR is a benchmark routinely evaluated in most hospitalised patients.

Materials and methods. 23 patients with a clinical diagnosis of PSP-RS, 18 patients with CBS, and 32 healthy controls, were included in the study. Blood samples were assessed in the context of neutrophil and lymphocyte rates. Subsequently, the results were transformed into neutrophil-to-lymphocyte ratio (NLR). The NLRs from each group were statistically assessed using a Kruskal-Wallis test and post-hoc analysis.

Results. Statistical analysis confirmed significant differences in NLR between PSP-RS and control group. No other significant differences were observed.

Clinical implications. The possible use of NLR in the additional examination of atypical parkinsonisms.

Conclusions. To the best of our knowledge, this is the first study comparing this aspect of neuroinflammation in PSP and CBS. It presents NLR as a promising non-specific parameter in neurodegenerative diseases.

Article available in PDF format

View PDF Download PDF file


  1. Fest J, Ruiter TR, Groot Koerkamp B, et al. The neutrophil-to-lymphocyte ratio is associated with mortality in the general population: The Rotterdam Study. Eur J Epidemiol. 2019; 34(5): 463–470.
  2. Li X, Liu C, Mao Z, et al. Predictive values of neutrophil-to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis. Crit Care. 2020; 24(1): 647.
  3. Ataç Uçar C, Gökçe Çokal B, Ünal Artık HA, et al. Comparison of neutrophil-lymphocyte ratio (NLR) in Parkinson's disease subtypes. Neurol Sci. 2017; 38(2): 287–293.
  4. Inci I, Kusbeci OY, Eskut N. The neutrophil-to-lymphocyte ratio as a marker of peripheral inflammation in progressive supranuclear palsy: a retrospective study. Neurol Sci. 2020; 41(5): 1233–1237.
  5. Tak AZ, Sengül Y. Evaluation of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in essential tremor. Ideggyogy Sz. 2019; 72(1-2): 33–38.
  6. Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013; 80(5): 496–503.
  7. Kovacs GG. Invited review: Neuropathology of tauopathies: principles and practice. Neuropathol Appl Neurobiol. 2015; 41(1): 3–23.
  8. Respondek G, Grimm MJ, Piot I, et al. Movement Disorder Society-Endorsed Progressive Supranuclear Palsy Study Group. Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies. Mov Disord. 2020; 35(1): 171–176.
  9. Alster P, Nieciecki M, Koziorowski D, et al. Is brain perfusion a differentiating feature in the comparison of Progressive Supranuclear Palsy Syndrome (PSPS) and Corticobasal Syndrome (CBS)? J Clin Neurosci. 2020; 77: 123–127.
  10. Alster P, Krzyżanowska E, Koziorowski D, et al. Difficulties in the diagnosis of four repeats (4R) tauopathic parkinsonian syndromes. Neurol Neurochir Pol. 2018; 52(4): 459–464.
  11. Iankova V, Respondek G, Saranza G, et al. Movement Disorder Society-endorsed PSP Study Group, Movement Disorder Society-Endorsed Progressive Supranuclear Palsy Study Group, Movement Disorder Society-endorsed PSP Study Group, Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017; 32(6): 853–864.
  12. VandeVrede L, Ljubenkov PA, Rojas JC, et al. Four-Repeat Tauopathies: Current Management and Future Treatments. Neurotherapeutics. 2020 [Epub ahead of print].
  13. Alster P, Madetko N, Koziorowski D, et al. Microglial Activation and Inflammation as a Factor in the Pathogenesis of Progressive Supranuclear Palsy (PSP). Front Neurosci. 2020; 14: 893.
  14. Henkel K, Karitzky J, Schmid M, et al. Imaging of activated microglia with PET and [11C]PK 11195 in corticobasal degeneration. Mov Disord. 2004; 19(7): 817–821.
  15. Ishizawa K, Dickson DW. Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration. J Neuropathol Exp Neurol. 2001; 60(6): 647–657.
  16. Josephs KA. Key emerging issues in progressive supranuclear palsy and corticobasal degeneration. J Neurol. 2015; 262(3): 783–788.
  17. Wadia PM, Lang AE. The many faces of corticobasal degeneration. Parkinsonism Relat Disord. 2007; 13 Suppl 3: S336–S340.
  18. Irwin DJ. Tauopathies as clinicopathological entities. Parkinsonism Relat Disord. 2016; 22 Suppl 1: S29–S33.
  19. Valotassiou V, Papatriantafyllou J, Sifakis N, et al. Brain perfusion SPECT with Brodmann areas analysis in differentiating frontotemporal dementia subtypes. Curr Alzheimer Res. 2014; 11(10): 941–954.
  20. Alster P, Nieciecki M, Koziorowski DM, et al. Thalamic and cerebellar hypoperfusion in single photon emission computed tomography may differentiate multiple system atrophy and progressive supranuclear palsy. Medicine (Baltimore). 2019; 98(30): e16603.